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1st Editorial Decision 05 December 2011 
Thank you for submitting your manuscript for consideration to EMBO Molecular Medicine. Three 
referees have now seen it, whose comments are shown below.  
 
As you will see, all three referees find your study of interest. However, they also raised a certain 
number of issues that are explicitly reported in the reviews. Nevertheless I would like to highlight 
few points that are particularly important for our journal:  
 
- Despite Ref. #1 recommendation to remove the human data, we would encourage you not to. 
Instead please provide additional information regarding intensity of staining and clarify p53 
mutation status (ref. #1)  
- Clarify the expression pattern of pAKT as associated with survival (ref. #2 major remark)  
- Amend nomenclature of tumor type and provide better images of different cancer types as 
recommended by Ref. #3  
 
I would like to invite you to submit a revised version of the manuscript, fully addressing the 
comments of all three reviewers, within the time constraints outlined below. Please note that it is 
EMBO Molecular Medicine policy to allow only a single round of major revision and that, as 
acceptance or rejection of the manuscript will depend on another round of review, your responses 
should be as complete as possible.  
 
Revised manuscripts should be submitted within three months of a request for revision; they will 
otherwise be treated as new submissions, except under exceptional circumstances in which a short 
extension is obtained from the editor.  
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I look forward to seeing a revised form of your manuscript as soon as possible.  
 
Yours sincerely,  
 
Editor  
EMBO Molecular Medicine  
 
 
***** Reviewer's comments *****  
 
Referee #1 (Comments on Novelty/Model System):  
 
All aspects of the mouse model are high, but the human studies require additional studies as my 
remarks below explain.  
 
Referee #1 (Other Remarks):  
 
This is an interesting manuscript that reports a novel and important genetic mouse model of Type II 
endometrial carcinoma. The authors created a Trp53 conditional knock-out strain that deletes Trp53 
in the epithelium of the genitourinary tract. The deletion of Trp53 resulted in Type II endometrial 
carcinomas arising in aged female mice. Not only did the mice develop invasive cancers of varied 
histologic appearances (serous, clear cell, MMMT) they also developed precursor lesions 
histologically similar to those seen in humans.  
 
In their initial attempts to characterize the mouse model the authors carried out some 
immunohistochemical analyses, which revealed activation of the Pi3k/Pten pathway in a significant 
subset of the tumors. To follow up these results, the authors undertook immunohistochemical 
analyses of a large number of primary human endometrial carcinomas using a TMA. They report 
that immunostaining with p53 is an independent predictor of outcome for endometrial carcinoma 
"that should be routinely employed by pathologists to assist with risk stratification of endometrial 
carcinoma".  
 
The mouse model is novel and should be published. However it is disappointing that there is not 
more of an attempt to characterize the mouse tumors beyond morphology and 
immunohistochemistry. It is this reviewer's opinion that it might be best to remove the human 
studies (for the reasons cited below) and report the mouse model as a brief communication or short 
report. This could then be followed by future studies further characterizing the mouse model. I have 
no doubt that this model will be a powerful tool for furthering our understanding of Type II tumors 
and will generate great interest in the field.  
 
Although the human studies are interesting they do not add much to the existing literature. It has 
been found in a number of previous studies (on smaller cohorts) that immunohistochemical staining 
for p53 is an independent prognostic marker for endometrial carcinoma. The authors suggest that 
what is new is that a number of Type I tumors stain for p53, although the majority show much less 
staining than serous tumors, and that this correlates with outcome. Given the novelty of this finding, 
additional supportive data are necessary. P53 immunohistochemistry is for the most part a surrogate 
marker for the presence of p53 mutations. It is generally accepted that missense mutations result in 
diffuse, intense staining while nonsense mutations lead to a complete absence of staining. It is not 
clear what less diffuse staining (i.e., scores of 1-10%, 11-50% and even 51-90%) translate to at the 
molecular level. Such molecular studies on at least a subset of the tumors are required. Additional 
studies on scoring the immunostaining needs to be done before such strong clinical 
recommendations can be made. This is especially important given the known problems with TMAs 
and their inability to reflect the heterogeneity of tumors.  
 
 
Finally, I think the authors point out something that is often not communicated well in the existing 
literature. That is: Grade 3 endometrioid tumors, although they may have arisen through a similar 
pathogenetic pathway as Grade 1 and 2 tumors, are best considered Type II tumors. This may in fact 
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be due to the acquisition of p53 mutations as several studies have shown that over half of Grade 3 
tumors have p53 mutations.  
 
In sum, the mouse model is novel and will be of interest to a large group of investigators. However, 
it has not been well characterized in this manuscript. But, since those studies are time and labor 
intensive, I would suggest publishing the mouse model in a short format. Furthermore, the human 
studies require additional studies and should be separated from the current mouse studies. They don't 
add significant novel data and only, in my opinion, dilute the impact of this powerful mouse model.  
 
 
 
Referee #2 (Comments on Novelty/Model System):  
 
This paper changes the way we stratify risk for type I endometrial cancer by introducing p53 as a 
novel negative predictor.  
Furthermore, the novel mouse model will help molecular and preclinical studies of type II cancers.  
 
Referee #2 (Other Remarks):  
 
This is a well-written manuscript describing the first mouse model of type II endometrial cancer, 
based on p53 ablation in the mouse endometrium.  
The authors convincingly show that, with age, these mice display the pathological and 
morphological progression observed in human patients, including the presence of the characteristic 
precursor lesions. In addition, they show rather frequent activation of the PI3K/mTOR pathway, 
more often in more advanced lesions, suggesting that this pathway cooperates with p53 loss to 
establish type II cancers, especially of the papillary type.  
The second part of the manuscript uses a large number of human samples to convincingly show that 
PI3K signaling is active not only in type I, but also in type II endometrial cancer. Furthermore, p53 
expression is validated as a sensitive marker for poor prognosis, even in type I cancers.  
In general, this paper represents an important contribution to our understanding of endometrial 
cancer pathogenesis, and to the development of better prognostic markers.  
 
MAJOR REMARKS  
It is striking that, in Fig. 5, p110alpha, pS6, p4E-BP1, and pGSK3beta all predict poor survival, 
while high pAKT is associated with better survival. This result represents a major inconsistency.  
 
MINOR REMARKS:  
A subset of tumors displays activation of mTOR targets without evidence of AKT activation, 
suggesting that an alternative pathway to mTOR activation may exist. This should be discussed.  
Page 6, second paragraph, third line: "...around 6 months of age (1F)". According to the figure 
legends, this picture corresponds to 10 weeks old mice. This point should be clarified.  
Table S1: The total number of patients/samples is listed as 515. However, adding the number of 
patients divided by age yields 520, and adding all the patients listed by FIGO stage yields 521.  
In the legend to Figure 2, "illustrating" is misspelled.  
Page 12, line 14: there is an extra semicolon (;).  
 
 
 
Referee #3 (Comments on Novelty/Model System):  
 
Wild et al in this study showed solid evidence of p53 gene function governs the aggressiveness of 
the endometrial carcinoma. The study design was good and the results are convincing. However, I 
do have the following comments for the authors to modify when they revise the manuscript.  
 
1. Abstract: Since the precursor lesions of EmGD and EIC are important findings in the study, the 
authors should cover the findings with a few more sentences in the abstract.  
2. Introduction and Discussion: There are several concepts about the endometrial cancer the authors 
need to understand clearly and modify the text and wording accordingly in the manuscript.  
a) Carcinosarcoma is currently classified into type II cancer category.  
b) Type II cancer develops in a stepwise fashion from latent precancer which is p53 signature 
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endometrial glands (Zhang X et al, 2009 and Jarboe et al., 2009) to precancer (EmGD), to non-
invasive cancer (EIC), and to full blown carcinoma (endometrial serous carcinoma). It is fine that 
your current study may not address the issue of latent precancer, but it should be addressed either in 
the Introduction or Discussion section. The word "precursor" is vague sometimes, particularly in this 
setting. For instance, EIC as a precursor for endometrial serous carcinoma can be misread as EIC as 
a precancer. In reality, EIC is a special form of endometrial serous carcinoma which is associated 
very high extrauterine disease frequency (Zheng and Schwartz 2005). The authors should use the 
term carefully in the text.  
c) EmGD represents an earliest morphologically identifiable precancerous lesion under microscope. 
Please make corresponding changes in line 6, second paragraph of page 8.  
d) Type II cancers develop mainly in elderly women. That is true. However, it is not necessary the 
background endometrium is always atrophic. This is mainly because many postmenopausal women 
are using hormone replacement or estrogen like food supplements, which ultimately change the 
endometrial proliferative status. In those conditions, Zheng et al called as resting endometrium in 
their publications (Zheng et al., 2011). Therefore, the first sentence in second paragraph on page 3 
should be modified accordingly.  
e) Serous carcinoma is the prototype cancer for type II endometrial cancer. Previously, papillary 
structure was emphasized. These days we know that it is not necessary for serous carcinoma always 
has papillary structures, while carcinomas with papillary structures are not necessary serous type. 
Therefore, the term uterine papillary serous carcinoma (UPSC) has been gradually dropped. The 
current most accepted term is endometrial serous carcinoma (ESC) by emphasizing the serous 
cellular changes rather than structures.  
3. Figures:  
a) Figure 1J: This is not a classic picture for a mixed serous and clear cell carcinoma mainly because 
the nuclear grade is too low.  
b) Figure 1K: I understand that this picture in the old days, many pathologists would diagnose it as 
endometrioid carcinoma. But nowadays it is diagnosed as serous carcinoma (glandular type) without 
problem since all tumor cells have high-grade nuclei.  
c) Figure 1N: This is also equal to a serous carcinoma with solid growth pattern.  
d) Figure 2B: This EmGD picture is not representative. It looks like EIC. The degree of nuclear 
atypia looks worse than EIC in figures 2C and 2G. By definition, the degree of nuclear atypia of 
EmGD falls short of EIC. The better pictures should be used. Many figures of EmGD in supplement 
data are good.  
 
4. Some specific points:  
a) Page 4, line 12, the reference Jarboe et al., 2009 does not belong to the text.  
b) Page 9, line 7 and others: "papillary EIC" is not a good term. The authors may use "EIC with 
papillary structures".  
c) Page 9, line 9: fibrogenic should be fibrovascular.  
d) Page 9, line 20 to 22: continuous transitions from normal looking endometrium to EmGD, to EIC, 
and to ESC was originally observed and described by Zheng et al. (2004). Therefore, it is not your 
proposal. Authors should give the credit to previous publication and state supported the previously 
proposed...  
e) Page 16, last sentence: It is too early to recommend that p53 staining is used in every endometrial 
cancer case. This will not be cost-effective. Therefore, authors should modify the sentence or 
remove it since authors have developed risk score strategy in this study, which is certainly superior 
than p53 staining alone in clinical setting.  
 
5. Some relevant questions:  
a) Since the authors generated genital-urinary tract specific deletion of Trp53, cancer or cancer like 
lesions are expected to be developed in other organs such as kidney and bladder. What were the 
general findings in addition to endometrial type II cancers? Authors should briefly mention in the 
text.  
b) In this mouse model, can authors describe the time (how many weeks) of EmGD starts prior to 
the observation of full brown type II cancer or EIC?  
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Referee # 1 
Although the human studies are interesting they do not add much to the existing literature. It has been 
found in a number of previous studies (on smaller cohorts) that immunohistochemical staining for p53 
is an independent prognostic marker for endometrial carcinoma. The authors suggest that what is new is 
that a number of Type I tumors stain for p53, although the majority show much less staining than serous 
tumors, and that this correlates with outcome. Given the novelty of this finding, additional supportive 
data are necessary. P53 immunohistochemistry is for the most part a surrogate marker for the presence 
of p53 mutations. It is generally accepted that missense mutations result in diffuse, intense staining 
while nonsense mutations lead to a complete absence of staining. It is not clear what less diffuse 
staining (i.e., scores of 1-10%, 11-50% and even 51-90%) translate to at the molecular level. Such 
molecular studies on at least a subset of the tumors are required. Additional studies on scoring the 
immunostaining needs to be done before such strong clinical recommendations can be made. This is 
especially important given the known problems with TMAs and their inability to reflect the 
heterogeneity of tumors. 
 
We disagree that our human cancer studies do not add much to the existing literature. We would like to 
emphasise that we have systematically analysed in a single cohort almost all of the markers that have 
been previously proposed to be involved in endometrial carcinoma pathogenesis. We identify that the 
mTOR pathway is frequently activated in type II tumours and that this is predictive of a poor outcome, 
highlighting a molecular similarity with type I tumours. Using this dataset we have also developed a 
novel statistical method to assess whether combinations of the 14 tested markers may yield more 
prognostic information than individual markers alone. Interestingly, this unbiased approach revealed 
that the immunohistochemical (IHC) status of p53 alone is almost an equally good predictive marker as 
the 4 protein signature, implying a fundamentally important role of p53 in the pathogenesis of both type 
I and type II tumours.  
 
We appreciate the reviewer’s comment that our IHC findings would be strengthened by molecular 
analyses of TP53 gene mutation status. To attempt to allow a molecular interpretation of IHC scores 
where only a fraction of the tumour cells stain strongly for p53 we undertook deep sequencing analyses 
of exons 5-8 of the TP53 gene in 63 endometrial carcinoma cases from endometrioid or serous 
carcinoma subtypes that displayed different frequencies of IHC staining. DNA was isolated from 
punches taken directly adjacent to the punches used for the TMA analysis to attempt to minimize 
heterogeneity between different regions of the tumour. The obtained depth of sequencing coverage (an 
average of over 2000 reads per amplicon) allowed insight into the heterogeneity of TP53 mutations 
present in each individual tumour. This data has been included as a new Figure 7 and new Supporting 
Information Table 2 in the manuscript and is described in the Results and Discussion sections. Briefly, 
this data shows that there is an excellent correlation between the frequency of TP53 mutations in the 
tumour and the IHC score, particularly for those cases with a strong IHC score. Moreover, we could 
show that there is an excellent correlation between mutations that are predicted to have a strong 
detrimental effect on protein function and the frequency of occurrence of these mutations within the 
tumour population, implying that these mutations provide a selective advantage to the tumour cells that 
leads to their enrichment in the tumour. Finally, tumours in which the most abundant mutation was 
present in more than 33% of the sequences had a much worse prognosis than those where the most 
abundant mutation was present at frequencies less than 33%.  
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Yemelyanova et al. (Modern Pathology, 2011, 24:1248-1253) similarly identified a correlation between 
a high p53 IHC score and the occurrence of TP53 mutations in ovarian carcinomas. These authors 
additionally identified that 31% of ovarian carcinomas that display completely negative p53 IHC 
staining are in fact associated with TP53 mutations (that presumably truncate or render the p53 protein 
unstable or alter the epitope detected by the antibody). In our endometrial carcinoma cases we also 
found that some negative p53 IHC score tumours contained TP53 mutations. However, the frequencies 
of these mutations were not highly abundant (compared to the frequencies found in tumours that 
displayed a high p53 IHC score) suggesting that i) these mutations either do not lead to aberrant 
stabilisation of the p53 protein or render the p53 protein unrecognisable by the p53 antibody and ii) that 
these mutations do not provide a selective advantage to the tumour cells that harbour them. This latter 
point is consistent with the good prognosis that p53 IHC negative tumours display in our survival 
analyses.  
 
Not surprisingly, we also identified tumours that display a strong p53 IHC score but which do not 
display an obvious dominant TP53 mutation. It is possible that these tumours may harbor mutations in 
TP53 exons that we have not sequenced, or that p53 may be aberrantly stabilized in these tumours due 
to alterations in one of the many regulatory pathways that control p53 protein stability and function (eg. 
loss or mutation of Mdm2). In this respect, we believe that p53 IHC has the advantage of being able to 
identify either TP53 mutations or other aberrations in the p53 pathway in endometrial tumours. In 
summary, we believe that these new gene mutation studies provide molecular evidence to support our 
proposal that p53 IHC status is an excellent predictive marker of endometrial carcinoma prognosis that 
could be employed routinely in the clinic. We also now provide new pictures in Supporting Information 
Figure 8 that show representative p53 IHC staining patterns for each IHC score to aid other 
investigators who may wish to perform similar studies on independent cohorts of tumours. 
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Referee #2 
MAJOR REMARKS 
It is striking that, in Fig. 5, p110alpha, pS6, p4E-BP1, and pGSK3beta all predict poor survival, while 
high pAKT is associated with better survival. This result represents a major inconsistency. 
We thank the reviewer for raising this pertinent question. An important point to clarify is that the PI3K-
AKT-mTORC1 signalling pathway should not be considered as a strictly linear cascade. There are 
numerous inputs into this pathway (amino acids, growth factors, cellular energy status, hypoxia) at 
different levels, as well as several points of negative feedback regulation, most prominently several 
mechanisms downstream of mTORC1 activation that involve S6K-mediated inactivation of IRS 
proteins or PDGF receptors. This feedback normally serves to balance the input and output signals 
to/from mTORC1. In the context of tumours, genetic alterations that lead to constitutive activation of 
mTORC1 (such as mutations or silencing of TSC1 or TSC2) cause constitutive feedback inhibition of 
AKT signaling (see Manning, 2004, JCB 3: 399-403). Thus, a lowered activation status of AKT can in 
some instances be a consequence of overactive mTORC1 signalling and AKT must be considered as 
being both upstream and downstream of mTORC1. 
 
We attempted to further clarify the activation status of the AKT kinases in our cohort of human tumour 
samples by IHC staining using antibodies against phospho-Thr-308 AKT (phosphorylation at this site 
results from activity of the PKD1 kinase and is necessary for AKT activation) and against phospho-
AKT substrate (this antibody recognizes phosphorylated moieties in substrates that are targeted by AKT, 
thus serving as a global readout of AKT kinase activity). Unfortunately, despite several attempts in our 
own staining facilities and using those of another diagnostic pathology unit in a hospital in Germany, 
we were unable to obtain reliable stainings for these antibodies. This is a recurring problem that we 
have observed when attempting to monitor AKT activity in a variety of different tumour types. The 
staining for all AKT activation markers is almost always very weak. We speculate that this may be 
partly due to the quality and sensitivity of the available antibodies but also in large part due to the 
aforementioned feedback inhibition mechanisms that act as a cellular “rheostat” to keep AKT activation 
at a low and appropriate level. 
 
Given that the AKT data are therefore less “concrete” than the mTORC1 activation status data (for 
which we have multiple downstream markers that show the same trend) we have altered the text in 
numerous places in the manuscript to remove the emphasis on the “PI3K-AKT-mTORC1” pathway and 
instead describe this either as the “mTORC1” pathway or to describe“PI3K and/or mTORC1 activation” 
depending on the relevant data set. This focus emphasizes that mTORC1 is the common downstream 
effector of several different genetic alterations that are known to occur in endometrial tumours (see also 
below). 
 
 
MINOR REMARKS: 
A subset of tumors displays activation of mTOR targets without evidence of AKT activation, 
suggesting that an alternative pathway to mTOR activation may exist. This should be discussed. 
We agree that this interpretation is one possibility (but see above for discussion regarding interpretation 
of AKT activation data). Indeed, as referenced in the manuscript, it has been reported that loss of TSC2 
or LKB1 expression occurs in 13% and 21% of type I endometrial tumours, respectively (Lu et al. 2008, 
Human Cancer Biology, 14:2543-2550). Genetic mutations in the LKB1-TSC1/2-Rheb signaling axis 
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can cause mTORC1 activation independently of AKT activation. We have now conducted IHC staining 
for TSC1 and TSC2 to test this possibility in our cohort of human endometrial tumours. This data has 
been included as new panels in Figures 4 and 5. While these studies show that some tumours have 
lower levels of expression than others, there are no major significant differences between subtypes of 
endometrial tumours, nor do these expression differences provide prognostic information. 
 
We believe that ultimately it will be necessary to perform studies in which comprehensive sequencing 
analyses are performed for each individual tumour on all of the genes that are known to be positive and 
negative regulators of the PI3K-AKT-mTORC1 signalling pathway or of other mTORC1 regulatory 
pathways. It is highly likely that there will be many different combinations of mutations or genetic 
alterations that lead to activation of some or all components of these signalling cascades in each 
individual tumour. Our IHC data obtained using P-S6 and P-4E-BP1 as the most downstream readouts 
of activation of mTORC1 should provide further impetus to undertake such ambitious analyses in 
future studies. 
 
 
Page 6, second paragraph, third line: "...around 6 months of age (1F)". According to the figure legends, 
this picture corresponds to 10 weeks old mice. This point should be clarified. 
The original figure legend was incorrect. The pictures are representative of 10 week old kidneys and 
uteri but of 6 month old epididymides. We have adapted the figure legend to clarify this. 
 
Table S1: The total number of patients/samples is listed as 515. However, adding the number of 
patients divided by age yields 520, and adding all the patients listed by FIGO stage yields 521. 
We apologise for this inconsistency. Supplementary Information Table 1 has been corrected 
(Ntotal=521). 
 
In the legend to Figure 2, "illustrating" is misspelled.  
This has been corrected. 
 
Page 12, line 14: there is an extra semicolon (;). 
This sentence has been corrected. 
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Referee #3  
 
However, I do have the following comments for the authors to modify when they revise the manuscript. 
 
1. Abstract: Since the precursor lesions of EmGD and EIC are important findings in the study, the 
authors should cover the findings with a few more sentences in the abstract. 
In principle we agree that this would be a good idea, but unfortunately this is not possible due to the 
strict word limit of the abstract. Defining “endometrial glandular dysplasia” and “endometrial intra-
epithelial carcinoma” in the abstract requires too many words and would take away from the other 
messages of the paper. We therefore chose to use the general term “precursor lesions” in the abstract 
and these have been well defined and discussed in the manuscript in several places. 
 
2. Introduction and Discussion: There are several concepts about the endometrial cancer the authors 
need to understand clearly and modify the text and wording accordingly in the manuscript. 
 
a) Carcinosarcoma is currently classified into type II cancer category. 
We thank the reviewer for raising this issue. In our study, three mice developed carcinosarcomas (Table 
1). This strongly confirms one of our major findings; i.e. the generation of a mouse model of type II 
endometrial cancer. Immunohistochemical and molecular studies strongly support the inclusion of 
uterine carcinosarcomas in the epithelial group, especially in the type II category of endometrial 
carcinomas. However, classification of carcinosarcomas as type II endometrial carcinoma is still a 
matter of debate. According to the WHO classification of tumours of the female genital tract (Tavassoli 
& Devilee (Eds.): World Health Organization Classification of Tumours. Pathology and Genetics of 
Tumours of the Breast and Female Genital Organs. IARC Press: Lyon 2003) uterine carcinosarcomas 
are separately classified as a mixed epithelial and mesenchymal neoplasm whose prognosis is worse 
than that of members of the epithelial category. This separate classification is also the case in a couple 
of current textbooks for gynecologic pathology (e.g.: Nucci & Oliva: Gynecologic Pathology. A 
Volume in Foundations in Diagnostic Pathology Series. Goldblum (Ed). Churchill Livingstone: 2009). 
Others include carcinosarcomas within the type II category (Dedes et al., Nat Rev Clin Oncol 2011). 
Nonetheless, we decided to keep carcinosarcomas as a separate tumour entity for our statistical analyses 
to be as precise and descriptive as possible.  
 
b) Type II cancer develops in a stepwise fashion from latent precancer which is p53 signature 
endometrial glands (Zhang X et al, 2009 and Jarboe et al., 2009) to precancer (EmGD), to non-invasive 
cancer (EIC), and to full blown carcinoma (endometrial serous carcinoma). It is fine that your current 
study may not address the issue of latent precancer, but it should be addressed either in the Introduction 
or Discussion section. The word "precursor" is vague sometimes, particularly in this setting. For 
instance, EIC as a precursor for endometrial serous carcinoma can be misread as EIC as a precancer. In 
reality, EIC is a special form of endometrial serous carcinoma which is associated very high 
extrauterine disease frequency (Zheng and Schwartz 2005). The authors should use the term carefully in 
the text. 
We appreciate this helpful clarification and have altered the relevant section of the Introduction 
accordingly as follows. “Endometrial serous adenocarcinomas are believed to arise from precursor 
lesions termed endometrial glandular dysplasia (EmGD) that progress to a non-invasive cancer termed 
endometrial intraepithelial carcinoma (EIC) (Fadare & Zheng, 2009; Zheng et al, 2007; Zheng et al, 
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2004; Zheng et al, 2011). Approximately 50-75% of these lesions display TP53 mutations (Jia et al, 
2008; Liang et al, 2004). p53 immunohistochemical signatures, termed latent precursors, can also be 
observed in benign endometrial glands, suggesting that TP53 mutation occurs as the very first step of 
serous adenocarcinoma formation {Jarboe, 2009 #358;Zhang, 2009 #357}.” 
 
c) EmGD represents an earliest morphologically identifiable precancerous lesion under microscope. 
Please make corresponding changes in line 6, second paragraph of page 8. 
This sentence has been changed as suggested. “EmGD represents the earliest morphologically 
identifiable serous carcinoma precancerous lesion in humans (Yi & Zheng, 2008; Zheng et al, 2004)” 
 
d) Type II cancers develop mainly in elderly women. That is true. However, it is not necessary the 
background endometrium is always atrophic. This is mainly because many postmenopausal women are 
using hormone replacement or estrogen like food supplements, which ultimately change the 
endometrial proliferative status. In those conditions, Zheng et al called as resting endometrium in their 
publications (Zheng et al., 2011). Therefore, the first sentence in second paragraph on page 3 should be 
modified accordingly. 
Thank you for this clarification. We have altered the sentence about the atrophic 
endometrium/estrogenic effect as this information is not directly relevant to the topic of the current 
paper. 
 
e) Serous carcinoma is the prototype cancer for type II endometrial cancer. Previously, papillary 
structure was emphasized. These days we know that it is not necessary for serous carcinoma always has 
papillary structures, while carcinomas with papillary structures are not necessary serous type. Therefore, 
the term uterine papillary serous carcinoma (UPSC) has been gradually dropped. The current most 
accepted term is endometrial serous carcinoma (ESC) by emphasizing the serous cellular changes rather 
than structures. 
We are aware of the nomenclature changes. According to the reviewer’s comment, we have changed 
the diagnoses in Figures 1 and 2 as well as in the manuscript. Growth patterns are now provided in 
brackets only. 
 
3. Figures: 
a) Figure 1J: This is not a classic picture for a mixed serous and clear cell carcinoma mainly because 
the nuclear grade is too low. 
We have replaced the picture in Figure 1J with a new image that shows the more typical high nuclear 
grade that we observe in these mouse tumours. 
 
b) Figure 1K: I understand that this picture in the old days, many pathologists would diagnose it as 
endometrioid carcinoma. But nowadays it is diagnosed as serous carcinoma (glandular type) without 
problem since all tumor cells have high-grade nuclei. 
We have changed the diagnosis in Figure 1K accordingly. The list of diagnoses in Table I has also been 
adjusted.  
 
c) Figure 1N: This is also equal to a serous carcinoma with solid growth pattern. 
The neoplasia in Figure 1N is a non-endometrioid (type II) endometrial cancer. Per definition, 
undifferentiated carcinomas are those lacking any evidence of differentiation (Tavassoli, Devilee (Eds.): 
 Page 8/11 
Institute of Physiology 
 
 
World Health Organization Classification of Tumours. Pathology and Genetics of Tumours of the 
Breast and Female Genital Organs. IARC Press: Lyon 2003) which is the case for the tumour in Figure 
1N. Therefore, we have designated the lesion as undifferentiated carcinoma rather than serous 
adenocarcinoma with solid growth pattern. Both entities in humans show a very poor clinical outcome 
and a distinction is in some respects an academic discussion. For the present type of study, however, it 
is important to be as precise as possible and to emphasize that some tumour lesions of our mouse model 
did not show any differentiation. 
 
d) Figure 2B: This EmGD picture is not representative. It looks like EIC. The degree of nuclear atypia 
looks worse than EIC in figures 2C and 2G. By definition, the degree of nuclear atypia of EmGD falls 
short of EIC. The better pictures should be used. Many figures of EmGD in supplement data are good. 
Thank you for this comment. We have replaced the images in 2B and 2C to better reflect the 
representative nuclear atypia that are characteristic of these types of lesions. We have attempted in the 
text of the manuscript to better emphasise that what we observe in the mouse are a spectrum of lesions 
that are consistent with increasing degree of malignancy in terms of nuclear morphology and structure 
of the epithelium. We have generally classified these precursor lesions based on the EmGD/EIC 
descriptors previously defined for human tissues. One benefit of the mouse model is that there are many, 
many lesions that may be observed. We therefore also observe some lesions within the malignant 
spectrum that exhibit overlapping features of both EmGD and EIC. 
 
4. Some specific points: 
a) Page 4, line 12, the reference Jarboe et al., 2009 does not belong to the text. 
Thank you. This mis-citation has been moved to the relevant position in the rewritten section of the 
Introduction (see point 2b for details). 
 
b) Page 9, line 7 and others: "papillary EIC" is not a good term. The authors may use "EIC with 
papillary structures". 
We have altered this term as suggested. 
 
c) Page 9, line 9: fibrogenic should be fibrovascular. 
This has been corrected. 
 
d) Page 9, line 20 to 22: continuous transitions from normal looking endometrium to EmGD, to EIC, 
and to ESC was originally observed and described by Zheng et al. (2004). Therefore, it is not your 
proposal. Authors should give the credit to previous publication and state “supported the previously 
proposed...” 
We agree completely with this point and it was not our intention to give the impression that this was a 
new idea but rather to illustrate that the mouse model is completely consistent with the proposed model 
in human disease. We have altered the relevant section of the results to better illustrate this point. 
“Based on their morphologies and relative frequencies of occurrence, it appears that these lesions 
represent a spectrum of histological changes that occur in the progression from a normal epithelium to a 
carcinoma, consistent with the model proposed for human endometrial serous adenocarcinoma {Zheng, 
2004 #354}. Papillary adenocarcinomas in our model appear to form exclusively from the surface 
epithelium of the lumen (Fig 2I) whereas adenocarcinomas with an acinar growth pattern arise from 
endometrial glands (Fig 2E). Supporting the progression model, and consistent with observations in 
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human disease {Zheng, 2004 #354}, the endometrial epithelium directly surrounding several papillary 
adenocarcinomas (Fig 3G shows an example) displays a continuous transition from normal epithelium 
(Fig 3J) to EmGD (Fig 3M) to EIC (Fig 3P) to a papillary adenocarcinoma growth pattern (Fig 3P).” 
 
e) Page 16, last sentence: It is too early to recommend that p53 staining is used in every endometrial 
cancer case. This will not be cost-effective. Therefore, authors should modify the sentence or remove it 
since authors have developed risk score strategy in this study, which is certainly superior than p53 
staining alone in clinical setting. 
We disagree with this suggestion that we should exclude the recommendation to perform p53 
immunohistochemistry. p53 IHC stainings are routine procedures in virtually all pathology laboratories 
worldwide. The cost-effectiveness is best determined by the prognostic value of the procedure. In our 
case we present convincing evidence that the prognostic value is extremely high. We would like to 
emphasise that we have systematically analysed in a single cohort almost all of the markers that have 
been previously proposed to be involved in endometrial carcinoma pathogenesis. We identify that the 
mTOR pathway is frequently activated in type II tumours and that this is predictive of a poor outcome, 
highlighting a molecular similarity with type I tumours. Using this dataset we have also developed a 
novel statistical method to assess whether combinations of the 14 tested markers may yield more 
prognostic information than individual markers alone. Interestingly, this unbiased approach revealed 
that the immunohistochemical (IHC) status of p53 alone is almost an equally good predictive marker as 
the 4 protein signature, implying a fundamentally important role of p53 in the pathogenesis of both type 
I and type II tumours.  
 
We appreciate the reviewer’s comment that our IHC findings would be strengthened by molecular 
analyses of TP53 gene mutation status. To attempt to allow a molecular interpretation of IHC scores 
where only a fraction of the tumour cells stain strongly for p53 we undertook deep sequencing analyses 
of exons 5-8 of the TP53 gene in 63 endometrial carcinoma cases from endometrioid or serous 
carcinoma subtypes that displayed different frequencies of IHC staining. DNA was isolated from 
punches taken directly adjacent to the punches used for the TMA analysis to attempt to minimize 
heterogeneity between different regions of the tumour. The obtained depth of sequencing coverage (an 
average of over 2000 reads per amplicon) allowed insight into the heterogeneity of TP53 mutations 
present in each individual tumour. This data has been included as a new Figure 7 and new Supporting 
Information Table S2 in the manuscript and is described in the Results and Discussion sections. Briefly, 
this data shows that there is an excellent correlation between the frequency of TP53 mutations in the 
tumour and the IHC score, particularly for those cases with a strong IHC score. Moreover, we could 
show that there is an excellent correlation between mutations that are predicted to have a strong 
detrimental effect on protein function and the frequency of occurrence of these mutations within the 
tumour population, implying that these mutations provide a selective advantage to the tumour cells that 
leads to their enrichment in the tumour. Finally, tumours in which the most abundant mutation was 
present in more than 33% of the sequences had a much worse prognosis than those where the most 
abundant mutation was present at frequencies less than 33%.  
 
Yemelyanova et al. (Modern Pathology, 2011, 24:1248-1253) similarly identified a correlation between 
a high p53 IHC score and the occurrence of TP53 mutations in ovarian carcinomas. These authors 
additionally identified that 31% of ovarian carcinomas that display completely negative p53 IHC 
staining are in fact associated with TP53 mutations (that presumably truncate or render the p53 protein 
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unstable or alter the epitope detected by the antibody). In our endometrial carcinoma cases we also 
found that some negative p53 IHC score tumours contained TP53 mutations. However, the frequencies 
of these mutations were not highly abundant (compared to the frequencies found in tumours that 
displayed a high p53 IHC score) suggesting that i) these mutations either do not lead to aberrant 
stabilisation of the p53 protein or render the p53 protein unrecognisable by the p53 antibody and ii) that 
these mutations do not provide a selective advantage to the tumour cells that harbour them. This latter 
point is consistent with the good prognosis that p53 IHC negative tumours display in our survival 
analyses.  
 
Not surprisingly, we also identified tumours that display a strong p53 IHC score but which do not 
display an obvious dominant TP53 mutation. It is possible that these tumours may harbor mutations in 
TP53 exons that we have not sequenced, or that p53 may be aberrantly stabilized in these tumours due 
to alterations in one of the many regulatory pathways that control p53 protein stability and function (eg. 
loss or mutation of Mdm2). In this respect, we believe that p53 IHC has the advantage of being able to 
identify either TP53 mutations or other aberrations in the p53 pathway in endometrial tumours. In 
summary, we believe that these new gene mutation studies provide molecular evidence to support our 
proposal that p53 IHC status is an excellent predictive marker of endometrial carcinoma prognosis that 
could be employed routinely in the clinic. We also now provide new pictures in Supporting Information 
Figure 8 that show representative p53 IHC staining patterns for each IHC score to aid other 
investigators who may wish to perform similar studies on independent cohorts of tumours. 
 
 
5. Some relevant questions: 
a) Since the authors generated genital-urinary tract specific deletion of Trp53, cancer or cancer like 
lesions are expected to be developed in other organs such as kidney and bladder. What were the general 
findings in addition to endometrial type II cancers? Authors should briefly mention in the text. 
To address this useful comment we have added the following sentence to the results section (page 6) 
“Trp53Δ/Δ mice displayed no pathological alterations in the kidney, ureter, bladder, vas deferens or 
vesicular glands up until at least 79 weeks of age.” 
The following sentences were added to the Discussion section “Trp53 gene deletion under the control 
of the Ksp1.3-Cre transgene occurs during embryogenesis and induces gene deletion widely in the 
kidney and genitourinary tract, yet tumours arise only in the endometrium in old mice, suggesting that 
additional genetic alterations must accumulate and cooperate with Trp53 deficiency to initiate cancer. 
The absence of tumours in tissues other than the endometrium likely reflects the very low rate of 
cellular turnover in these tissues in comparison to the cyclic nature of cellular proliferation in the 
endometrium, which presumably allows mutations to frequently accumulate in the absence of p53 
function.” 
 
 
b) In this mouse model, can authors describe the time (how many weeks) of EmGD starts prior to the 
observation of full blown type II cancer or EIC? 
Thank you for this excellent question. We have added a new Supporting Information Figure S1 that 
depicts representative lesions that are observed in mice at different ages. These observations are now 
described in the results section (page 9/10) by the following sentences. “Furthermore, all mice in the 
24-29 week-old cohort displayed some regions of EmGD (Supporting Information Fig 1E,H,N,Q) and 
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all mice in the 47-58 week-old cohort frequently displayed widespread regions of EmGD and/or EIC 
(Supporting Information Fig 1F,I,O,R) but did not display any tumours. Thus, as they age, Trp53-
deficient mice progressively display a spectrum of endometrial histological alterations ranging from 
low nuclear grade dysplasia through to invasive high grade carcinomas. These mice therefore represent 
the first model that accurately reproduces the progression and hallmark morphological features of 
human type II endometrial carcinomas.” 
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2nd Editorial Decision 20 April 2012 
Thank you for the submission of your revised manuscript to EMBO Molecular Medicine. We have 
now received the enclosed reports from the referees that were asked to re-assess it. As you will see 
the reviewers are now globally supportive and I am pleased to inform you that we will be able to 
accept your manuscript pending the following final amendments:  
 
As you will see below, two referees are not fully satisfied with statements regarding the novelty and 
recommendation of systematically use p53 staining on endometrial carcinomas. We would 
appreciate if you could tune down these statements in the main text of the manuscript.  
 
Please submit your revised manuscript within two weeks. I look forward to seeing a revised form of 
your manuscript as soon as possible.  
 
I look forward to reading a new revised version of your manuscript as soon as possible.  
 
Yours sincerely,  
Editor  
EMBO Molecular Medicine  
 
 
***** Reviewer's comments *****  
 
Referee #1 (Comments on Novelty/Model System):  
 
I maintain my opinion about the human data. It is not novel and their recommendation of staining 
every endometrial carcinoma with p53 is not convincing.  
 
Referee #1 (Other Remarks):  
 
Despite the authors rebuttal of the data on the human tumors what they have done is not novel. All 
of these markers have been previously looked at in primary human tumors. The association of 
positive p53 immunohistochemical staining with poor prognosis has been known for almost 2 
decades, including the relationship of IHC staining and mutations (it has been shown in endometrial 
carcinoma that negative IHC staining correlates with nonsense mutations, you don't need to cite 
recent ovarian cancer data). Furthermore, many of the PTEN/AKT/PI3K downstream effectors have 
been studied at the protein and gene expression level.  
Therefore, I maintain that mouse model is very powerful and novel and should be characterized and 
correlated with human tumors. That is what makes this manuscript important and valuable.  
 
 
Referee #2 (Comments on Novelty/Model System):  
 
The authors have addressed the points raised by the reviewers.  
 
Referee #2 (Other Remarks):  
 
The points raised by the three reviewers have been adequately addressed, and the manuscript is now 
acceptable for publication.  
 
 
Referee #3 (Other Remarks):  
 
After extensive revision, the manuscript reaches to the publication level. However, I still insist that 
one statement on page 15, last sentence of the first paragraph, should be modified. It is too early to 
recommend that p53 staining is used in every endometrial cancer case in the clinic. This kind of 
recommendation typically derives from large scale clinical trials, which is certainly not applied to 
current study.  
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2nd Revision - Authors' Response 20 April 2012 
Referee #1 (Comments on Novelty/Model System):  
 
I maintain my opinion about the human data. It is not novel and their recommendation of staining 
every endometrial carcinoma with p53 is not convincing.  
 
Referee #1 (Other Remarks):  
 
Despite the authors rebuttal of the data on the human tumors what they have done is not novel. All 
of these markers have been previously looked at in primary human tumors. The association of 
positive p53 immunohistochemical staining with poor prognosis has been known for almost 2 
decades, including the relationship of IHC staining and mutations (it has been shown in endometrial 
carcinoma that negative IHC staining correlates with nonsense mutations, you don't need to cite 
recent ovarian cancer data). Furthermore, many of the PTEN/AKT/PI3K downstream effectors have 
been studied at the protein and gene expression level.  
Therefore, I maintain that mouse model is very powerful and novel and should be characterized and 
correlated with human tumors. That is what makes this manuscript important and valuable.  
 
 
Referee #2 (Comments on Novelty/Model System):  
 
The authors have addressed the points raised by the reviewers.  
 
Referee #2 (Other Remarks):  
 
The points raised by the three reviewers have been adequately addressed, and the manuscript is now 
acceptable for publication.  
 
 
Referee #3 (Other Remarks):  
 
After extensive revision, the manuscript reaches to the publication level. However, I still insist that 
one statement on page 15, last sentence of the first paragraph, should be modified. It is too early to 
recommend that p53 staining is used in every endometrial cancer case in the clinic. This kind of 
recommendation typically derives from large scale clinical trials, which is certainly not applied to 
current study. 
 
Regarding the comments of reviewer 1 and reviewer 3 we have modified the relevant sections of the 
text according to the suggestions to remove the emphasis on the novelty and strength of the clinical 
recommendations. The relevant sections now read as follows: 
 
Page 15: In this study, p53 immunoreactivity therefore represents a highly sensitive and predictive 
marker that assists with risk stratification of endometrial carcinomas. 
 
Page 19: In summary, irrespective of endometrial carcinoma subtype, grade or FIGO stage, we find 
that strong p53 nuclear immunoreactivity represents an excellent marker to stratify patients into poor 
outcome groups, even in low grade and low FIGO stage tumours. We suggest that these patients, 
who would otherwise be stratified into a relatively low-risk group, should actually be considered as 
high-risk patients who would benefit from additional monitoring and therapy, possibly including the 
use of drugs to inhibit the PI3K pathway and/or strategies to kill p53 deficient tumour cells (Lane et 
al, 2010). We suggest that further clinical studies should investigate the possible value of 
performing p53 immunohistochemistry as a routine procedure to assist with risk stratification of 
endometrial carcinomas.  
 
The Paper Explained: We have removed the clinical recommendation from the IMPACT section. 
 
 
Regarding the additional comments of reviewer 1 we believe that our manuscript already does 
highlight the points that the reviewer makes. We cite the relevant literature in which others have 
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previously studied similar markers in these tumour types. We agree that the major novelty of our 
paper is that the mouse model closely correlates with the molecular and histological features of 
human tumours and have already highlighted these issues in numerous places in the text. We do not 
believe that any further manuscript changes are necessary to address this opinion of the reviewer. 
 
 
 
 
 
 
 
 
 
 
 
